STATegics’ product pipeline is focused on allosteric small molecule modulators of clinically and commercially relevant cytokine receptors.  STATegics’ lead programs target cytokine receptors that have been shown to play fundamentally important roles in cell survival, differentiation and neuronal function.

STATegics has discovered small molecule mimetics with erythropoietin (EPO)-like neuronal effects.  Preclinical studies performed by STATegics and its collaborators have indicated beneficial effects of the lead compounds in several cellular models of neurological disorders.  The program has been partially funded by grants from the National Institute of Neurological Disorders and Stroke (NINDS), Department of Defense and the Friedreich's Ataxia Research Alliance (FARA). 

STATegics is also advancing a 2nd generation thrombopoietin (TPO) mimetic in preclinical studies with the potential to address significant needs in the treatment of patients with low platelet counts.  Data from the company’s proprietary TPO mimetic compounds (US 2008/0139621) were presented at the 2008 Annual Meeting of American Society of Hematology  (Blood, 112: Abstract 2888, 2008).  STATegics' US patent No. 7,786,159 covering the lead compounds was issued in August 2010.     

STATegics’ strategy is to advance its proprietary compounds through preclinical stages and early clinical development independently, while seeking to work in partnership with other biotechnology and pharmaceutical companies toward later stage development and commercialization.